公开(公告)号：US06680332B1

公开(公告)日：2004-01-20

申请号：US09980628

申请日：2002-05-20

申请人： Christopher S. Konkoy ,  David B. Fick ,  Sui Xiong Cai ,  Nancy C. Lan ,  John F. W. Keana

发明人： Christopher S. Konkoy ,  David B. Fick ,  Sui Xiong Cai ,  Nancy C. Lan ,  John F. W. Keana

IPC分类号： A61K4364

CPC分类号： C07D311/74

摘要： Disclosed is a method for treating a disorder responsive to the positive modulation of AMPA receptors in animals suffering therefrom, comprising administering to an animal in need thereof a compound of Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is NH2, NHR, and NHCOR; Z is O and S; and R1, R2, R3, R4, and X are defined herein. These compounds can be used as cognitive enhancers, for the treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, AIDS associated dementia and Down's syndrome as well as for the treatment of schizophrenia and myoclonus. Also disclosed are pharmaceutical compositions useful for treating disorders responsive to the positive modulation of AMPA receptors, and novel compounds of Formula I.

摘要翻译： 本发明公开了一种治疗患有AMPA受体AMPA受体阳性调节的病症的方法，其包括向有需要的动物施用式I化合物或其药学上可接受的盐或前药，其中：Y为NH 2， NHR和NHCOR; Z是O和S; 并且R1，R2，R3，R4和X在本文中定义。 这些化合物可用作认知增强剂，用于治疗神经变性疾病，包括阿尔茨海默病，肌萎缩性侧索硬化，亨廷顿舞蹈病，帕金森病，AIDS相关性痴呆和唐氏综合征，以及治疗精神分裂症和肌阵挛。 还公开了可用于治疗对AMPA受体的正调节起反应的病症的药物组合物和式I的新化合物。